Tabelecleucel
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner. It is made of cells of the immune system called T-cells that have been taken from a donor (allogeneic) and are then mixed with EBV-infected B-cells from the same donor. The most common side effects include fever, diarrhea, fatigue, nausea (feeling sick), anemia (low red blood cell count), reduced appetite, hyponatremia (low sodium levels in the blood), abdominal pain, low white blood cell count, including neutrophils (white blood cells that fight infections), elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase (indicators of potential liver damage), constipation, hypoxia (low blood oxygen levels), dehydration, hypotension (low blood pressure), nasal congestion, and rash. Tabelecleucel was approved for medical use in the European Union in December 2022.
Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner. It is made of cells of the immune system called T-cells that have been taken from a donor (allogeneic) and are then mixed with EBV-infected B-cells from the same donor. The most common side effects include fever, diarrhea, fatigue, nausea (feeling sick), anemia (low red blood cell count), reduced appetite, hyponatremia (low sodium levels in the blood), abdominal pain, low white blood cell count, including neutrophils (white blood cells that fight infections), elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase (indicators of potential liver damage), constipation, hypoxia (low blood oxygen levels), dehydration, hypotension (low blood pressure), nasal congestion, and rash. Tabelecleucel was approved for medical use in the European Union in December 2022.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1344275052 under CC BY-SA 4.0; modifications have been made.